Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does EMPAGLIFLOZIN Cause Low density lipoprotein increased? 11 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 11 reports of Low density lipoprotein increased have been filed in association with EMPAGLIFLOZIN (Jardiance). This represents 0.0% of all adverse event reports for EMPAGLIFLOZIN.

11
Reports of Low density lipoprotein increased with EMPAGLIFLOZIN
0.0%
of all EMPAGLIFLOZIN reports
0
Deaths
2
Hospitalizations

How Dangerous Is Low density lipoprotein increased From EMPAGLIFLOZIN?

Of the 11 reports, 2 (18.2%) required hospitalization.

Is Low density lipoprotein increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for EMPAGLIFLOZIN. However, 11 reports have been filed with the FAERS database.

What Other Side Effects Does EMPAGLIFLOZIN Cause?

Diabetic ketoacidosis (3,644) Fungal infection (1,941) Blood glucose increased (1,797) Euglycaemic diabetic ketoacidosis (1,769) Weight decreased (1,661) Urinary tract infection (1,439) Ketoacidosis (1,411) Dizziness (1,372) Nausea (1,333) Vomiting (1,201)

What Other Drugs Cause Low density lipoprotein increased?

EVOLOCUMAB (1,024) INCLISIRAN (423) ALIROCUMAB (336) ROSUVASTATIN (241) ATORVASTATIN (217) EZETIMIBE (217) LOMITAPIDE (164) TOFACITINIB (135) FINGOLIMOD (132) SOMATROPIN (93)

Which EMPAGLIFLOZIN Alternatives Have Lower Low density lipoprotein increased Risk?

EMPAGLIFLOZIN vs EMPAGLIFLOZIN\LINAGLIPTIN EMPAGLIFLOZIN vs EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN EMPAGLIFLOZIN vs EMPAGLIFLOZIN\METFORMIN EMPAGLIFLOZIN vs EMSAM EMPAGLIFLOZIN vs EMTRICITABINE

Related Pages

EMPAGLIFLOZIN Full Profile All Low density lipoprotein increased Reports All Drugs Causing Low density lipoprotein increased EMPAGLIFLOZIN Demographics